A randomized, double-blind, placebo-controlled trial published in Nature Communications tested whether losartan and prednisolone can influence post-COVID syndrome and signs of cardiac inflammation. Led by Victor O. Puntmann and Eike Nagel, the study evaluated two already-approved drugs in a setting where long COVID’s cardiovascular sequelae remain a key clinical and research gap. The trial results add to the evidence base on whether anti-hypertensive and corticosteroid strategies can modulate persistent symptoms and measurable cardiac inflammation markers. Repurposing trials like this are closely watched because they can rapidly inform clinical practice or redirect combination strategies in post-acute care.